Nice pipeline and catalysts (see image below).
The company does have analysts following it and there are a total of 6 Buy ratings and no Sell ratings.
Shares recently rocketing over 30% after TXMD management team met with the FDA to talk about resubmitting an NDA for TX-004HR in dyspareunia. Oppenheimer analyst Jay Olson thinks the FDA meeting went well and that the company is now “back on track as best-case regulatory scenario emerges.” Jay Olson reiterates his Outperform rating on TXMD stock with a $10 price target.
There is an absence of large players volume. Large players dumped the stock back at the end of September and they still have not come back.
I would add the stock to your watch list and monitor the large players volume.